Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease.
Vilya has raised $21.0M in total funding. The most recent round was Series A. The last funding was announced in June 2024.
Vilya's investors include Menlo Ventures, Madrona, ARCH Venture Partners, Lifeforce Capital, NVentures.
Vilya is headquartered in Seattle, United States.
Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease.
Vilya is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vilya — Funding & Investors." VCBacked, June 4, 2024, https://www.vcbacked.co/company/vilya. Accessed October 26, 2026.
VCBacked. (2024). Vilya — Funding & Investors. Retrieved October 26, 2026, from https://www.vcbacked.co/company/vilya
{{cite web |title=Vilya — Funding & Investors |url=https://www.vcbacked.co/company/vilya |website=VCBacked |access-date=October 26, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated